{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009849","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.854028+00:00","generated_at":"2026-06-17T09:07:07.176120+00:00","sec_items":["2.02","7.01","1.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INVO Bioscience prelim Q4 revenue $270-280K, up 15-19% QoQ; signs Wisconsin clinic acquisition","bullets":["Q4 2022 revenue expected $270K-$280K, up 15-19% from Q3 2022's $235K.","Full year 2022 revenue expected $815K-$825K, up 38-40% YoY excluding $3.6M deferred revenue from Ferring.","Gross operating expenses for FY2022 expected $10.5M-$11.0M, up 14-19% YoY.","Signed binding purchase agreement for Wisconsin Fertility Institute (clinic generated ~$5.5M revenue, $1.9M net income in trailing 12 months).","Closed registered direct offering for ~$3M gross proceeds in March 2023; 10-K filing extended to April 15, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009849","json":"https://secwatch.observer/filing/0001493152-23-009849.json","markdown":"https://secwatch.observer/filing/0001493152-23-009849.md","text":"https://secwatch.observer/filing/0001493152-23-009849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223009849/0001493152-23-009849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223009849/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:07:07.176120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc3fd2ba3029fd1b1440c1dab255b923771d505e","claim":"INVO Fertility, Inc. reported preliminary financial results for fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, INVO Bioscience, Inc. (the \"Company\") issued a press release announcing preliminary financial results for the fourth quarter and the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223009849/0001493152-23-009849-index.htm","confidence":0.96,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}